The purpose of the study is to measure the effect of the amlodipine/atorvastatin combination pill in reducing both elevated blood pressure and cholesterol levels to levels suggested by guidelines

Condition	Intervention	Phase
Hypertension Hyperlipidemia	Drug: Amlodipine/atorvastatin single pill	Phase III

Further Study Details: 

Primary Outcomes: To evaluate the efficacy of amlodipine/atorvastatin therapy by assessing the percentage of intent-to-treat subjects achieving both blood pressure and lipid treatment goals as defined by Joint National Committee (JNC) Guidelines (Report VII) and National
Secondary Outcomes: To assess changes from baseline in LDL-C, total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), HDL C/LDL C ratio, SBP and DBP after 14 weeks of open-label treatment. To assess the percentage of intent-to-treat subjects achie
Expected Total Enrollment:  1825

Ages Eligible for Study:  18 Years   -   80 Years,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

• Clinical diagnosis of both elevated blood pressure and low density lipoprotein cholesterol levels, requiring medication

Exclusion Criteria:

• Patients with blood pressure adequately maintained at goal with or without medication
• Patients currently treated with both amlodipine and atorvastatin or not at blood pressure or lipid level while taking the highest dose of amlodipine or atorvastatin, respectively

Study chairs or principal investigators

Pfizer CT.gov Call Center,  Study Director,  Pfizer   

Study ID Numbers:  A3841024
Last Updated:  September 1, 2005
Record first received:  August 31, 2005
ClinicalTrials.gov Identifier:  NCT00143234
Health Authority: Taiwan: Department of Health
ClinicalTrials.gov processed this record on 2005-09-13